Clinical Trials Logo

Lung Neuroendocrine Neoplasm clinical trials

View clinical trials related to Lung Neuroendocrine Neoplasm.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03600233 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Start date: December 15, 2018
Phase: Phase 2
Study type: Interventional

CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.

NCT ID: NCT03110978 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

Start date: June 26, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well stereotactic body radiation therapy with or without nivolumab works in treating patients with stage I-IIA non-small cell lung cancer or cancer that has come back. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy and nivolumab may work better at treating non-small cell lung cancer.